Drug Profile
ME 143
Alternative Names: ME-143; NV-143Latest Information Update: 12 Dec 2017
Price :
$50
*
At a glance
- Originator Novogen
- Developer MEI Pharma
- Class Antineoplastics; Isoflavones; Small molecules
- Mechanism of Action NADH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 13 Apr 2016 Discontinued - Phase-I for Solid tumours in USA (IV)
- 28 Jun 2012 Marshall Edwards is now called MEI Pharma
- 01 Jun 2012 Marshall Edwards completes a phase I trial in Solid tumours (refractory disease) in USA (NCT01401868)